Source pharma APIs & nutraceutical ingredients from India

Analgesic and antipyretic API, IP/BP/USP grades, 25 kg drums.

Oncology API (EGFR inhibitor). Prescription product — documentation required.

potent topical corticosteroid ester — cream, ointment and lotion formulations for inflammatory dermatoses.

ornithine decarboxylase inhibitor — cream formulations for facial hirsutism.

melanin synthesis inhibitor — cream formulations for hyperpigmentation, alone and in combinations.

13-cis retinoic acid — capsule formulations for severe recalcitrant acne.

depigmenting agent — cream formulations for universal depigmentation in vitiligo.

first-generation retinoid — cream and gel formulations for acne and photoageing, and oncology topicals.

proton pump inhibitor — capsule and pellet formulations for acid-peptic disorders.

5-HT3 antagonist antiemetic — tablet, syrup and injection formulations for chemotherapy and post-operative nausea.

gastric lipase inhibitor — capsule formulations for weight management.

non-absorbed oral antibiotic — tablet formulations for hepatic encephalopathy and IBS-D.

skeletal muscle relaxant acting on GABA-B receptors — tablet and suspension formulations for spasticity of spinal and cerebral origin.

dopamine D2 agonist — tablet formulations for hyperprolactinaemia.

reproductive hormone glycoprotein — injection formulations for fertility induction and hypogonadism.

mixture of conjugated equine estrogens — tablet formulations for hormone therapy.

potent systemic glucocorticoid — tablet and injection formulations across inflammatory, oncology and endocrine use.

primary female sex hormone — transdermal and tablet formulations for hormone therapy.

ester of estradiol for depot therapy — injection formulations for hormone therapy.

synthetic estrogen — tablet formulations within combined oral contraceptives and hormone therapy.

human menopausal gonadotropin — FSH and LH activity — injection formulations for controlled ovarian stimulation.

intermediate-acting glucocorticoid — tablet and injection formulations for inflammatory and autoimmune conditions.

recombinant human growth hormone — injection formulations for growth hormone deficiency.

centrally acting skeletal muscle relaxant — short-course tablet formulations for musculoskeletal pain.

long-acting testosterone ester — injection formulations for testosterone replacement.

long-acting testosterone ester — injection formulations for testosterone replacement.

synthetic steroid with estrogenic, progestogenic and androgenic activity — tablet formulations for menopausal symptoms.

mTOR inhibitor immunosuppressant — tablet and oral solution formulations for transplant rejection prophylaxis.

CYP17 inhibitor — tablet formulations for metastatic castration-resistant prostate cancer.

irreversible ErbB family blocker — tablet formulations for EGFR-mutated non-small cell lung cancer.

aromatase inhibitor — tablet formulations for hormone receptor-positive breast cancer in postmenopausal women.

glycopeptide cytotoxic antibiotic — injection formulations for lymphomas and germ cell tumours.

oral fluoropyrimidine prodrug — tablet formulations for colorectal, breast and gastric cancer.

second-generation BCR-ABL inhibitor — tablet formulations for chronic myeloid leukaemia and Ph+ ALL.

tricyclic skeletal muscle relaxant — tablet formulations for acute musculoskeletal spasm.

EGFR tyrosine kinase inhibitor — tablet formulations for non-small cell lung cancer and pancreatic cancer.

steroidal aromatase inactivator — tablet formulations for postmenopausal breast cancer.

recombinant G-CSF — injection formulations for neutropenia and stem-cell mobilisation.

LHRH agonist — implant formulations for prostate and breast cancer.

5-HT3 antagonist antiemetic — injection and tablet formulations for chemotherapy-induced nausea.

first-generation BCR-ABL inhibitor — tablet formulations for chronic myeloid leukaemia and GIST.

epothilone microtubule inhibitor — injection formulations for metastatic breast cancer.

immunomodulatory imide drug — capsule formulations for multiple myeloma and myelodysplastic syndromes.

multikinase inhibitor — capsule formulations for thyroid and hepatocellular carcinoma.

non-steroidal aromatase inhibitor — tablet formulations for postmenopausal breast cancer.

volatile inhalation anaesthetic — inhalation anaesthesia in veterinary and select human applications.

nitrogen mustard alkylating agent — tablet and injection formulations for multiple myeloma and transplant conditioning.

antifolate antimetabolite — tablet and injection formulations across oncology, rheumatology and dermatology.

antifolate antimetabolite — injection formulations for non-small cell lung cancer and mesothelioma.

CXCR4 antagonist for stem-cell mobilisation — injection formulations supporting autologous transplant collection.

hydrazine alkylating agent — capsule formulations for Hodgkin lymphoma and brain tumours.

multikinase inhibitor — tablet formulations for hepatocellular and renal cell carcinoma.

selective estrogen receptor modulator — tablet formulations for hormone receptor-positive breast cancer.

anti-HER2 monoclonal antibody — injection formulations for HER2-positive breast and gastric cancer.

fluoroquinolone developed for ophthalmic use — suspension formulations for bacterial conjunctivitis.

prostaglandin analogue — eye drop formulations for glaucoma and for lash growth.

COX-2 selective NSAID — capsule formulations for osteoarthritis and rheumatoid arthritis.

alpha-2 adrenergic agonist — eye drop formulations for open-angle glaucoma, alone and with timolol.

calcineurin inhibitor immunomodulator — eye drop formulations for dry-eye disease, and systemic immunosuppression.

prostaglandin F2alpha analogue — eye drop formulations for glaucoma first-line therapy.

glucocorticoid for ocular inflammation — eye drop formulations for uveitis and post-operative inflammation.

mast-cell stabiliser — eye drop formulations for allergic conjunctivitis.

selective norepinephrine reuptake inhibitor — capsule formulations for attention deficit hyperactivity disorder.

SNRI — capsule formulations for depression, anxiety, neuropathic pain and fibromyalgia.

SSRI — tablet and solution formulations for depression and anxiety disorders.

SSRI — capsule formulations for depression, OCD and bulimia.

SSRI with sigma-receptor activity — tablet formulations for OCD and anxiety disorders.

potent short-duration NSAID — injection and tablet formulations for short-term post-operative pain.

nicotine replacement active — gum and lozenge formulations for smoking cessation.

SSRI — tablet formulations for depression, anxiety and OCD.

atypical antipsychotic — tablet formulations for schizophrenia, bipolar disorder and as adjunct in depression.

SNRI — tablet and capsule formulations for depression and anxiety disorders.

theophylline–ethylenediamine complex bronchodilator — injection and tablet formulations for reversible airway obstruction.

non-halogenated corticosteroid for inhalation — inhaler, respule and nasal formulations for asthma and rhinitis.

synthetic thyroid hormone — tablet formulations for hypothyroidism.

second-generation PDE5 inhibitor — tablet formulations for erectile dysfunction.

hyperglycosylated erythropoiesis-stimulating protein — injection formulations for anaemia of chronic kidney disease.

recombinant erythropoietin — injection formulations for renal anaemia and oncology supportive care.

enolic-acid NSAID preferring COX-2 — tablet and suspension formulations for osteoarthritis and ankylosing spondylitis.

intravenous iron carbohydrate complex — injection formulations for iron deficiency at high single doses.

type II 5-alpha reductase inhibitor — tablet formulations for benign prostatic hyperplasia and male-pattern hair loss.

intravenous iron polysaccharide complex — injection formulations for iron deficiency in dialysis and CKD.

PEGylated erythropoiesis-stimulating agent — injection formulations for renal anaemia on extended dosing intervals.

first PDE5 inhibitor — tablet formulations for erectile dysfunction and pulmonary arterial hypertension.

long-acting PDE5 inhibitor — tablet formulations for erectile dysfunction, BPH and pulmonary arterial hypertension.

selective alpha-1A blocker — capsule formulations for benign prostatic hyperplasia.

PDE5 inhibitor — tablet formulations for erectile dysfunction.

central antispastic agent — tablet formulations for spasticity and myofascial pain.

semi-synthetic colchicoside muscle relaxant — tablet and capsule formulations for painful muscle spasm.

aminoglycoside antibiotic — injection formulations for serious gram-negative infections.

central alpha-2 agonist muscle relaxant — tablet formulations for spasticity and muscle spasm.

phenylacetic-acid NSAID — tablet formulations for osteoarthritis and rheumatoid pain.

acetylsalicylic acid NSAID and antiplatelet — tablet formulations for pain, fever and cardiovascular prevention.

COX-2 selective NSAID — tablet formulations for arthritis and gout.

propionic-acid NSAID — capsule and gel formulations for musculoskeletal pain.

oxicam NSAID — tablet formulations for short-course acute pain.

fenamate NSAID — tablet formulations for dysmenorrhoea and musculoskeletal pain.

propionic-acid NSAID — tablet formulations for arthritis and musculoskeletal pain.

proteolytic enzyme — adjunct tablet formulations for inflammation and oedema.

centrally acting opioid analgesic — capsule, tablet and injection formulations for moderate to severe pain.

aminopenicillin beta-lactam antibiotic — injection and capsule formulations across human and veterinary use.

oral third-generation cephalosporin — suspension and capsule formulations for paediatric respiratory infections.

third-generation oral cephalosporin — tablet and suspension formulations for typhoid and urinary infections.

third-generation injectable cephalosporin — injection formulations for severe respiratory, CNS and urinary infections.

third-generation anti-pseudomonal cephalosporin — injection formulations for pseudomonal and febrile-neutropenia cover.

third-generation injectable cephalosporin — injection formulations for serious systemic infections.

second-generation cephalosporin — tablet and suspension formulations for respiratory and ENT infections.

penicillinase-resistant penicillin — capsule and injection formulations for staphylococcal infections.

tetracycline-class antibiotic — capsule and tablet formulations for infections, acne and malaria prophylaxis.

macrolide antibiotic — tablet and suspension formulations, including for penicillin-allergic patients.

levo-isomer fluoroquinolone antibiotic — tablet and injection formulations for respiratory and urinary infections.

First-line type 2 diabetes API for tablets and sustained-release forms.

monobactam antibiotic for gram-negative cover — injection formulations, including for patients with penicillin allergy.

oxazolidinone antibiotic — tablet and injection formulations for MRSA and VRE cover.

carbapenem antibiotic — injection formulations for severe multi-resistant infections.

nitroimidazole antibacterial and antiprotozoal — tablet, suspension and injection formulations for anaerobic and protozoal infections.

tetracycline-class antibiotic — tablet formulations for acne and resistant infections.

fluoroquinolone antibiotic — tablet formulations for urinary tract infections.

fluoroquinolone antibiotic — tablet and ear/eye drop formulations for bacterial infections.

ureidopenicillin — injection formulations, typically with tazobactam, for hospital infections.

semi-synthetic macrolide antibiotic — tablet formulations for respiratory and skin infections.

sulfonamide antibacterial — tablet formulations, typically combined with trimethoprim.

beta-lactamase inhibitor — combination partner for piperacillin and cephalosporins.

long-acting penicillin salt — injection formulations for syphilis therapy and rheumatic-fever prophylaxis.

tetracycline-class antibiotic — capsule formulations for acne and selected infections.

nitroimidazole antibacterial and antiprotozoal — tablet formulations for amoebiasis, giardiasis and anaerobic infections.

dihydrofolate-reductase-inhibitor antibacterial — tablet formulations for urinary tract infections.

thienopyridine antiplatelet — tablet formulations for post-stent and arterial thrombosis prevention.

antifibrinolytic haemostatic — tablet and injection formulations for surgical bleeding and menorrhagia.

vitamin-K-antagonist oral anticoagulant — tablet formulations for atrial fibrillation, DVT and mechanical valves.

sulfonylurea hypoglycaemic — tablet formulations, including modified-release, for type 2 diabetes.

meglitinide insulin secretagogue — tablet formulations for post-prandial glucose control.

DPP-4 inhibitor — tablet formulations for type 2 diabetes, alone and in combinations.

imidazole antifungal — cream, powder and pessary formulations for dermatophyte and candidal infections.

second-generation oral cephalosporin — capsule and suspension formulations for respiratory and ENT infections.

triazole antifungal — capsule and injection formulations for candidiasis and cryptococcosis.

sedating first-generation antihistamine — tablet and syrup formulations for allergy and cold symptoms.

non-sedating second-generation antihistamine — tablet and syrup formulations for allergic rhinitis and urticaria.

isoquinoline anthelmintic — tablet formulations for tapeworm and fluke infections.

first-line antitubercular — tablet formulations in first-line TB therapy.

hydrazide antitubercular — tablet formulations in first-line TB therapy.

nicotinamide-analogue antitubercular — tablet formulations in the intensive phase of first-line TB therapy.

rifamycin antitubercular — capsule formulations in first-line TB therapy.

azapeptide HIV protease inhibitor — capsule formulations for HIV-1, boosted with ritonavir.

integrase strand-transfer inhibitor — tablet formulations, the backbone of modern HIV therapy.

fourth-generation cephalosporin — injection formulations for febrile neutropenia and hospital infections.

non-nucleoside reverse-transcriptase inhibitor — tablet formulations in first-line antiretroviral therapy.

nucleoside reverse-transcriptase inhibitor — capsule and combination formulations for HIV and PrEP.

RNA-polymerase inhibitor — tablet formulations under emergency-use protocols for viral infections.

HIV protease inhibitor — tablet formulations co-formulated with ritonavir.

SARS-CoV-2 protease inhibitor — tablet formulations co-packed with ritonavir for COVID-19.

neuraminidase inhibitor — capsule and suspension formulations for influenza treatment.

HIV protease inhibitor and booster — tablet formulations as the pharmacokinetic booster of antiretroviral regimens.

nucleoside reverse-transcriptase inhibitor — tablet and syrup formulations for HIV, including prevention of mother-to-child transmission.

dihydropyridine calcium-channel blocker — tablet formulations for hypertension and angina.

cardioselective beta-blocker — tablet formulations for hypertension and chronic heart failure.

third-generation oral cephalosporin — tablet and suspension formulations for community-acquired infections.

cardiac glycoside — tablet formulations for atrial fibrillation and heart failure.

non-dihydropyridine calcium-channel blocker — tablet formulations for angina and rate control.

ACE inhibitor — tablet formulations for hypertension and heart failure.

loop diuretic — tablet and injection formulations for oedema in heart, liver and kidney disease.

thiazide diuretic — tablet formulations for hypertension, usually in combinations.

angiotensin II receptor blocker — tablet formulations for hypertension and diabetic nephropathy.

ACE inhibitor — tablet formulations for hypertension and post-infarction care.

angiotensin II receptor blocker — tablet formulations for hypertension and diabetic nephropathy.

cardioselective beta-blocker, extended-release salt — tablet formulations for hypertension, angina and heart failure.

angiotensin II receptor blocker — tablet formulations for hypertension.

first-generation cephalosporin — capsule and suspension formulations for skin and urinary infections.

non-selective beta-blocker — tablet formulations for hypertension, tremor, migraine prophylaxis and anxiety symptoms.

ACE inhibitor — tablet formulations for hypertension and cardiovascular prevention.

statin HMG-CoA reductase inhibitor — tablet formulations for hypercholesterolaemia.

statin HMG-CoA reductase inhibitor — tablet formulations for hypercholesterolaemia and cardiovascular prevention.

aldosterone-antagonist diuretic — tablet formulations for heart failure, ascites and resistant hypertension.

angiotensin II receptor blocker — tablet formulations for hypertension and cardiovascular risk reduction.

loop diuretic — tablet formulations for oedema and heart failure.

non-dihydropyridine calcium-channel blocker — tablet formulations for angina, hypertension and supraventricular arrhythmia.

sodium-channel antiepileptic — tablet and controlled-release formulations for focal seizures and trigeminal neuralgia.

peripheral dopa-decarboxylase inhibitor — combination partner of levodopa.

fluoroquinolone antibiotic — tablet, injection and ophthalmic formulations across a wide infection range.

acetylcholinesterase inhibitor — tablet formulations for Alzheimer-type dementia.

sodium-channel-stabilising antiepileptic — tablet formulations for focal seizures and bipolar maintenance.

broad-spectrum antiepileptic — tablet and solution formulations for focal and generalised seizures.

dopamine precursor — tablet formulations, with carbidopa, for Parkinson's disease.

endogenous sleep-cycle hormone — supplement formulations for jet lag and sleep-onset support.

NMDA-receptor antagonist — tablet formulations for moderate-to-severe dementia.

dopamine agonist — tablet formulations for Parkinson's disease and restless legs syndrome.

sulfa-substituted antiepileptic — tablet formulations for seizures and migraine prophylaxis.

broad-spectrum antiepileptic — tablet and syrup formulations for generalised and focal seizures.

pseudomonic acid topical antibiotic — ointment formulations for impetigo and nasal-colonisation control.

macrolide antibiotic — tablet and suspension formulations for respiratory infections and H. pylori regimens.

pyrethroid pediculicide and scabicide — cream and lotion formulations for scabies and lice.

fat-soluble vitamin C ester — antioxidant for oils, fats and lipid formulations.

aromatic carboxylic acid preservative — precursor for sodium benzoate and preservative systems.

tricarboxylic organic acid — effervescents, acidity control and chelation in food and pharma.

alpha-hydroxy acid — pH regulation, dermatology formulations and food preservation.

metallic stearate lubricant — tablet-press lubrication, typically 0.25–1% w/w.

fruit hydroxy-diacid — flavour enhancement and pH control in foods.

six-carbon sugar alcohol — tablet diluent, chewables and osmotic-diuretic presentations.

fruit-derived gelling polysaccharide — gelling, stabilising and fibre-fortification applications.

water-soluble sorbate preservative — preservative for beverages, dairy and topical pharma.

lincosamide antibiotic — capsule, injection and topical formulations for anaerobic and staphylococcal infections.

amorphous silica — flow aid, anti-caking and desiccant applications.

water-soluble benzoate preservative — preservative for syrups, beverages and liquid pharma.

unsaturated fatty-acid preservative — mould and yeast control in foods.

hydrated magnesium silicate — glidant, lubricant and dusting-powder applications.

grape-derived dihydroxy diacid — effervescent systems and baking powders.

inorganic white pigment opacifier — tablet film coatings and opacification.

peripheral dopamine-antagonist prokinetic — tablet and suspension formulations for nausea and gastroparesis.

S-isomer proton-pump inhibitor — tablet and capsule formulations for reflux disease and peptic ulcer.

H2-receptor antagonist — tablet and injection formulations for gastric acid suppression.

prokinetic dopamine antagonist — tablet formulations for functional dyspepsia.

aminoglycoside antibiotic — injection and ophthalmic formulations for gram-negative infections.

proton-pump inhibitor — capsule formulations for acid-related disorders.

5-aminosalicylic acid — tablet and enema formulations for ulcerative colitis.

5-HT4-agonist prokinetic — tablet formulations for dyspepsia and gastroparesis.

proton-pump inhibitor — tablet formulations for reflux and ulcer disease, often with domperidone.

H2-receptor antagonist — tablet and injection formulations for acid-related disorders.

hydrophilic bile acid — tablet formulations for gallstones and cholestatic liver disease.

selective oestrogen-receptor modulator — tablet formulations for ovulation induction.

short-acting corticosteroid — tablet, cream and injection formulations for inflammation, allergy and adrenal replacement.

natural progestogen — capsule and injection formulations for luteal support and HRT.

purine antimetabolite immunosuppressant — tablet formulations for transplant rejection prevention and autoimmune disease.

Broad-spectrum penicillin API, compacted and powder grades.

direct thrombin inhibitor prodrug — capsule formulations for stroke prevention in atrial fibrillation and DVT therapy.

mycophenolic-acid prodrug immunosuppressant — capsule formulations for transplant rejection prevention.

non-steroidal antiandrogen — tablet formulations for prostate cancer with GnRH therapy.

platinum chemotherapy agent — injection formulations for ovarian and lung cancer.

taxane antimicrotubule agent — injection concentrate for breast, lung and prostate cancer.

anthracycline cytotoxic antibiotic — injection formulations for solid tumours and leukaemias.

nucleoside-analogue antimetabolite — injection formulations for pancreatic, lung and breast cancer.

topoisomerase I inhibitor — injection formulations for colorectal cancer.

taxane antimicrotubule agent — injection formulations for ovarian, breast and lung cancer.

multi-target tyrosine-kinase inhibitor — capsule formulations for renal cell carcinoma and GIST.

non-selective beta-blocker — eye-drop formulations for glaucoma.

direct factor Xa inhibitor — tablet formulations for atrial fibrillation, DVT and PE.

short-acting benzodiazepine anxiolytic — tablet formulations for anxiety and panic disorder under controlled-drug rules.

tricyclic antidepressant — tablet formulations for depression, neuropathic pain and migraine prophylaxis.

dopamine partial-agonist antipsychotic — tablet formulations for schizophrenia, bipolar disorder and adjunct use in depression.

long-acting benzodiazepine — tablet formulations for seizures and panic disorder under controlled-drug rules.

noradrenergic and specific serotonergic antidepressant — tablet formulations for depression with sleep disturbance.

atypical antipsychotic — tablet formulations for schizophrenia and bipolar disorder.

atypical antipsychotic — tablet and solution formulations for schizophrenia and mania.

SSRI antidepressant — tablet formulations for depression, anxiety and OCD.

Z-drug hypnotic — tablet formulations for short-term insomnia under controlled-drug rules.

mucolytic secretolytic — syrup and tablet formulations for productive cough.

alpha-glucosidase inhibitor — tablet formulations for post-meal glucose control in type 2 diabetes.

levo-isomer short-acting beta-2 agonist — inhaler and nebuliser formulations for bronchospasm with reduced systemic load.

leukotriene-receptor antagonist — tablet and granule formulations for asthma and allergic rhinitis.

short-acting beta-2 agonist — inhaler, nebuliser solution and tablet formulations for bronchospasm.

dual 5-alpha-reductase inhibitor — capsule formulations for benign prostatic hyperplasia.

beta-3 adrenergic agonist — tablet formulations for overactive bladder.

selective alpha-1A blocker — capsule formulations for benign prostatic hyperplasia.

muscarinic M3 antagonist — tablet formulations for overactive bladder.

indole-acetic-acid NSAID — capsule and suppository formulations for arthritis, gout and patent ductus closure.

prototype opioid analgesic — tablet, solution and injection formulations for severe pain under controlled-drug rules.

sulfonanilide NSAID — tablet and suspension formulations for short-course acute pain and inflammation.

SGLT2 inhibitor — tablet formulations for type 2 diabetes.

COX-2 selective injectable NSAID — injection formulations for post-operative pain.

oxicam NSAID — capsule and gel formulations for osteoarthritis and rheumatoid pain.

first-generation injectable cephalosporin — injection formulations for surgical prophylaxis and staphylococcal infections.

beta-lactamase inhibitor — combination partner of amoxicillin and ticarcillin formulations.

polymyxin last-line antibiotic — injection formulations for carbapenem-resistant gram-negative infections.

cyclic lipopeptide antibiotic — injection formulations for complicated bacteraemia and skin infections.

phosphonic-acid antibacterial — sachet and injection formulations for urinary tract infections and MDR cover.

fusidane steroid-antibiotic — cream, ointment and tablet formulations for staphylococcal skin and bone infections.

fourth-generation fluoroquinolone antibiotic — tablet, injection and eye-drop formulations for respiratory and ocular infections.

nitrofuran urinary antibacterial — capsule formulations, including macrocrystals, for uncomplicated UTI.

SGLT2 inhibitor — tablet formulations for type 2 diabetes, heart failure and chronic kidney disease.

nitroimidazole antiprotozoal — tablet and infusion formulations for amoebiasis, giardiasis and anaerobic cover.

beta-lactamase inhibitor — combination partner for cefoperazone and ampicillin injections.

glycopeptide antibiotic — injection formulations for gram-positive infections including MRSA.

glycylcycline antibiotic — injection formulations for complicated skin and intra-abdominal infections.

glycopeptide antibiotic — injection formulations for MRSA and serious gram-positive infections.

DPP-4 inhibitor — tablet formulations for type 2 diabetes, alone and in combinations.

SGLT2 inhibitor — tablet formulations for type 2 diabetes.

GLP-1 receptor agonist peptide — injection pen formulations for type 2 diabetes and weight management.

sulfonylurea hypoglycaemic — tablet formulations for type 2 diabetes.

sulfonylurea hypoglycaemic — tablet formulations, including extended-release, for type 2 diabetes.

SGLT2 inhibitor — tablet formulations for type 2 diabetes and heart failure.

GLP-1 receptor agonist peptide — injection and tablet formulations for type 2 diabetes and weight management.

dual GIP/GLP-1 receptor agonist peptide — injection pen formulations for type 2 diabetes and weight management.

alpha-glucosidase inhibitor — tablet formulations for post-prandial glucose control.

morpholine antifungal — nail lacquer and cream formulations for onychomycosis and tinea.

hydroxypyridone antifungal — cream, lacquer and shampoo formulations for tinea and onychomycosis.

imidazole antifungal — cream formulations for dermatophyte and candidal skin infections.

oral systemic antifungal — tablet formulations for scalp and nail dermatophyte infections.

imidazole antifungal — cream formulations for tinea pedis, cruris and corporis.

allylamine antifungal — cream and gel formulations for dermatophyte skin infections.

polyene antifungal — oral suspension and topical formulations for candidiasis.

DPP-4 inhibitor — tablet formulations for type 2 diabetes.

diarylquinoline anti-TB agent — tablet formulations for multidrug-resistant tuberculosis regimens.

second-line anti-TB agent — capsule formulations for drug-resistant tuberculosis.

nitroimidazole anti-TB agent — tablet formulations for multidrug-resistant tuberculosis regimens.

second-line anti-TB agent — tablet formulations for drug-resistant tuberculosis.

second-line anti-TB agent — granule and tablet formulations for drug-resistant tuberculosis.

nucleoside reverse-transcriptase inhibitor — tablet and solution formulations for HIV-1, typically with lamivudine.

adamantane antiviral and dopaminergic — capsule formulations for influenza A and adjunct use in Parkinson's disease.

integrase strand-transfer inhibitor — single-tablet regimen component for HIV-1.

non-nucleoside reverse-transcriptase inhibitor — tablet formulations for HIV-1 therapy.

HCV NS5A inhibitor — tablet formulations, with grazoprevir, for hepatitis C.

sulfonylurea — tablet formulations for type 2 diabetes, alone and in combinations.

non-nucleoside reverse-transcriptase inhibitor — tablet formulations for treatment-experienced HIV patients.

prodrug of penciclovir — tablet formulations for herpes zoster and genital herpes.

nucleoside-analogue antiviral — capsule and injection formulations for CMV disease.

HCV NS3/4A protease inhibitor — tablet formulations, with pibrentasvir, for pan-genotypic hepatitis C.

HCV NS3/4A protease inhibitor — tablet formulations, with elbasvir, for hepatitis C.

immune-response modifier — cream formulations for genital warts and actinic keratosis.

ribonucleoside-analogue antiviral — capsule formulations for early COVID-19 under authorised protocols.

non-nucleoside reverse-transcriptase inhibitor — tablet and suspension formulations for HIV-1 therapy.

HCV NS5A inhibitor — tablet formulations, with glecaprevir, for pan-genotypic hepatitis C.

integrase strand-transfer inhibitor — tablet formulations for HIV-1 therapy.

rapid-acting insulin analogue — penfill and vial formulations for mealtime insulin cover.

non-nucleoside reverse-transcriptase inhibitor — tablet formulations in second-line antiretroviral regimens.

HCV NS3/4A protease inhibitor — tablet formulations in hepatitis C combination therapy.

carbonic-anhydrase inhibitor — tablet and injection formulations for glaucoma, altitude sickness and oedema.

dual endothelin-receptor antagonist — tablet formulations for pulmonary arterial hypertension.

angiotensin II receptor blocker — tablet formulations for hypertension and heart failure.

non-selective beta-blocker with alpha-blockade — tablet formulations for heart failure and hypertension.

thiazide-like diuretic — tablet formulations for hypertension, alone and in combinations.

antiplatelet and vasodilator — tablet formulations, typically with aspirin, for stroke prevention.

alpha-1 blocker — tablet formulations for hypertension and benign prostatic hyperplasia.

multichannel antiarrhythmic — tablet formulations for atrial fibrillation maintenance.

ultra-long-acting insulin analogue — pen formulations for basal insulin therapy.

selective aldosterone antagonist — tablet formulations for heart failure and post-infarction care.

cholesterol-absorption inhibitor — tablet formulations, alone and with statins, for hypercholesterolaemia.

PPAR-alpha agonist fibrate — tablet and capsule formulations for hypertriglyceridaemia.

thiazide-like diuretic — tablet formulations for hypertension.

long-acting nitrate vasodilator — extended-release tablet formulations for angina prophylaxis.

funny-channel (If) inhibitor — tablet formulations for angina and heart-failure rate control.

calcium sensitiser inotrope — infusion formulations for acute decompensated heart failure.

central alpha-2 agonist antihypertensive — tablet formulations for hypertension in pregnancy.

cardioselective beta-blocker with NO activity — tablet formulations for hypertension and heart failure.

short-acting nitrate vasodilator — sublingual tablet and spray formulations for acute angina.

Macrolide antibiotic API for tablets, suspensions and injectables.

long-acting insulin analogue — pen and vial formulations for basal insulin therapy.

statin HMG-CoA reductase inhibitor — tablet formulations for hypercholesterolaemia.

thienopyridine antiplatelet — tablet formulations for post-angioplasty stent cover.

late-sodium-current inhibitor — extended-release tablet formulations for chronic angina.

beta-blocker with class III antiarrhythmic action — tablet formulations for arrhythmia maintenance.

direct-acting P2Y12 antiplatelet — tablet formulations for acute coronary syndromes.

glutamatergic relapse-prevention agent — tablet formulations for alcohol-dependence maintenance.

selective synaptic-vesicle 2A ligand — tablet formulations for focal-onset seizures.

partial opioid agonist — sublingual tablet and patch formulations for pain and dependence therapy.

central muscle relaxant — tablet formulations, typically with paracetamol, for muscle spasm.

fourth-generation calcium-channel blocker — tablet formulations for hypertension, N- and L-type channels.

intermediate-acting human insulin — vial and pen formulations for basal insulin therapy.

phospholipid intermediate — tablet formulations for stroke recovery and cognitive support.

ryanodine-receptor antagonist — capsule and injection formulations for malignant hyperthermia and spasticity.

NF-E2-related-factor-2 activator — capsule formulations for relapsing multiple sclerosis.

potent synthetic opioid — transdermal patch and injection formulations for severe pain under controlled-drug rules.

sphingosine-1-phosphate receptor modulator — capsule formulations for relapsing multiple sclerosis.

slow sodium-channel inactivation antiepileptic — tablet and injection formulations for focal seizures.

full opioid agonist — tablet and solution formulations for opioid-dependence therapy.

opioid antagonist — injection formulations for opioid overdose reversal.

opioid antagonist — tablet formulations for alcohol and opioid-dependence relapse prevention.

cerebroselective calcium-channel blocker — tablet formulations for delayed cerebral ischaemia after aneurysmal bleed.

DPP-4 inhibitor with renal clearance profile — tablet formulations for type 2 diabetes.

anticholinergic muscle relaxant — tablet formulations for painful musculoskeletal spasm.

sodium-channel antiepileptic — tablet and suspension formulations for focal seizures.

AMPA-receptor antagonist — tablet formulations for focal and generalised seizures.

barbiturate antiepileptic — tablet and injection formulations for generalised and focal seizures.

hydantoin antiepileptic — tablet, capsule and injection formulations for seizure control.

irreversible MAO-B inhibitor — tablet formulations for Parkinson's disease.

glutamate-modulating agent — tablet formulations for amyotrophic lateral sclerosis.

dual cholinesterase inhibitor — capsule, patch and solution formulations for Alzheimer-type dementia.

non-ergot dopamine agonist — tablet formulations for Parkinson's disease and restless legs syndrome.

MAO-B inhibitor — tablet formulations as adjunct therapy in Parkinson's disease.

GLP-1 receptor agonist — pen formulations for type 2 diabetes and weight management.

5-HT1B/1D agonist triptan — tablet and injection formulations for acute migraine.

mu-opioid agonist and noradrenaline reuptake inhibitor — tablet formulations, including extended-release, for moderate to severe pain.

dihydro-orotate dehydrogenase inhibitor — tablet formulations for relapsing multiple sclerosis.

sulfonamide antiepileptic — capsule formulations for focal seizures.

third-generation topical retinoid — gel formulations for acne, alone and with benzoyl peroxide.

dicarboxylic acid keratolytic — cream and gel formulations for acne, rosacea and hyperpigmentation.

biguanide antiseptic — solution, gel and scrub formulations for skin prep, wound care and oral hygiene.

potassium-channel-opener vasodilator — topical solution and foam formulations for androgenetic alopecia.

beta-hydroxy keratolytic acid — cream, solution and peel formulations for acne, warts and keratotic disorders.

prototypical antimuscarinic alkaloid — injection formulations for bradycardia, organophosphate poisoning and pre-anaesthesia.

thiazolidinedione — tablet formulations for insulin resistance in type 2 diabetes.

diphenylmethane stimulant laxative — tablet and suppository formulations for short-term constipation relief.

PDE4-inhibiting antispasmodic — tablet and injection formulations for biliary, intestinal and dysmenorrhoeic spasm.

anticholinergic antispasmodic — tablet and injection formulations for visceral spasm and motion sickness.

non-absorbed disaccharide — syrup formulations for constipation and hepatic encephalopathy.

peripheral mu-opioid agonist antidiarrhoeal — capsule formulations for acute non-infective diarrhoea.

osmotic polyethylene-glycol laxative — powder sachets, with electrolytes, for constipation and bowel preparation.

central and peripheral prokinetic — tablet and injection formulations for nausea, vomiting and gastroparesis.

farnesoid-X-receptor agonist bile acid — tablet formulations for primary biliary cholangitis.

5-HT4-agonist enterokinetic — tablet formulations for chronic constipation unresponsive to laxatives.

thionamide antithyroid agent — tablet formulations for hyperthyroidism.

DPP-4 inhibitor — tablet formulations for type 2 diabetes, alone and in combinations.

super-potent topical corticosteroid — cream and ointment formulations for severe dermatoses, short-course.

potent synthetic corticosteroid — inhaler, nasal spray and cream formulations for asthma, rhinitis and dermatoses.

second-generation progestogen — tablet and intrauterine-system formulations for contraception.

synthetic T3 thyroid hormone — tablet formulations for hypothyroidism and myxoedema coma adjunct.

thionamide antithyroid agent — tablet formulations for hyperthyroidism.

antiprogestogen — tablet formulations, with misoprostol, under licensed obstetric protocols.

prostaglandin E1 analogue — tablet formulations for obstetric indications and gastric protection.

nonapeptide uterotonic hormone — injection formulations for labour induction and postpartum bleeding.

intermediate-acting corticosteroid — tablet formulations for inflammatory, allergic and autoimmune conditions.

thionamide antithyroid agent — tablet formulations for hyperthyroidism, including first trimester.

DPP-4 inhibitor — tablet formulations for type 2 diabetes.

medium-potency corticosteroid — cream, injection and dental paste formulations for inflammation and dermatoses.

macrolide calcineurin inhibitor — capsule and injection formulations for transplant immunosuppression, and ointment for atopic dermatitis.

JAK1/2 inhibitor — tablet formulations for rheumatoid arthritis and atopic dermatitis.

proteasome inhibitor — injection formulations for multiple myeloma and mantle-cell lymphoma.

nitrogen-mustard alkylating agent — tablet and injection formulations for haematologic and solid malignancies.

nucleoside-analogue antimetabolite — injection formulations for acute leukaemias.

androgen-receptor signalling inhibitor — tablet formulations for castration-resistant prostate cancer.

topoisomerase II inhibitor — capsule and injection formulations for lung cancer, lymphoma and germ-cell tumours.

mTOR inhibitor — tablet formulations for renal, breast and neuroendocrine tumours, and transplant immunosuppression.

antimetabolite fluoropyrimidine — injection and topical formulations for solid tumours and actinic keratosis.

triazole antifungal — capsule and solution formulations for systemic and nail fungal infections.

Bruton tyrosine-kinase inhibitor — capsule and tablet formulations for B-cell malignancies.

oxazaphosphorine alkylating agent — injection formulations with mesna cover for sarcomas and testicular cancer.

BCR-ABL tyrosine-kinase inhibitor — capsule formulations for chronic myeloid leukaemia.

third-generation EGFR inhibitor — tablet formulations for EGFR-mutated non-small-cell lung cancer.

CDK4/6 inhibitor — capsule and tablet formulations with endocrine therapy for HR-positive breast cancer.

multi-target tyrosine-kinase inhibitor — tablet formulations for renal cell carcinoma and soft-tissue sarcoma.

multi-kinase inhibitor — tablet formulations for colorectal cancer and GIST after prior therapy.

JAK1/2 inhibitor — tablet formulations for myelofibrosis and polycythaemia vera.

imidotetrazine alkylating agent — capsule formulations for glioblastoma and astrocytoma.

topoisomerase I inhibitor — injection and capsule formulations for ovarian, lung and cervical cancer.

imidazole antifungal — tablet and topical formulations, including shampoo forms.

BCL-2 inhibitor — tablet formulations for chronic lymphocytic leukaemia and acute myeloid leukaemia.

vinca alkaloid antimicrotubule agent — injection formulations for Hodgkin lymphoma and germ-cell tumours.

vinca alkaloid antimicrotubule agent — injection formulations for leukaemias and lymphomas.

semi-synthetic vinca alkaloid — injection formulations for non-small-cell lung and breast cancer.

topical carbonic-anhydrase inhibitor — eye-drop formulations for glaucoma.

topical carbonic-anhydrase inhibitor — eye-drop formulations for glaucoma.

prostaglandin F2-alpha analogue — eye-drop formulations for open-angle glaucoma and ocular hypertension.

norepinephrine-dopamine reuptake inhibitor — tablet formulations for depression and smoking cessation.

5-HT1A partial agonist anxiolytic — tablet formulations for generalised anxiety without sedation.

1,5-benzodiazepine — tablet formulations for anxiety and adjunct therapy in seizures.

allylamine antifungal — tablet and cream formulations for dermatophyte infections.

atypical antipsychotic — tablet formulations for treatment-resistant schizophrenia under monitoring protocols.

SNRI antidepressant — extended-release tablet formulations for major depression.

long-acting benzodiazepine — tablet and injection formulations for anxiety, muscle spasm and status epilepticus.

typical antipsychotic — tablet and injection formulations for psychosis and acute agitation.

intermediate-acting benzodiazepine — tablet and injection formulations for anxiety and acute agitation.

central stimulant — tablet formulations, including extended-release, for ADHD under controlled-drug rules.

ultra-short-acting benzodiazepine — injection and buccal formulations for sedation and acute seizures.

wakefulness-promoting agent — tablet formulations for narcolepsy and shift-work sleep disorder.

serotonin antagonist-reuptake inhibitor — tablet formulations for depression with insomnia.

thiol mucolytic and antioxidant — effervescent tablet, solution and injection formulations for mucolysis and paracetamol overdose.

Statin API for cholesterol-lowering tablets, amorphous and crystalline.

second-generation triazole — tablet and injection formulations for invasive aspergillosis and candidiasis.

long-acting beta-2 agonist, fast onset — inhalation formulations, typically with budesonide, for asthma and COPD.

once-daily long-acting beta-2 agonist — inhalation capsule formulations for COPD maintenance.

short-acting antimuscarinic bronchodilator — inhaler and nebuliser solution formulations for COPD and asthma.

long-acting beta-2 agonist — inhalation formulations, with fluticasone, for asthma and COPD.

short-acting beta-2 agonist — tablet and injection formulations for bronchospasm.

methylxanthine bronchodilator — tablet formulations, including sustained-release, for asthma and COPD.

long-acting antimuscarinic bronchodilator — inhalation capsule formulations for COPD maintenance.

selective alpha-1 blocker — tablet formulations for benign prostatic hyperplasia.

xanthine-oxidase inhibitor — tablet formulations for gout and tumour-lysis prophylaxis.

oral tridentate iron chelator — tablet formulations for transfusional iron overload.

first-generation antihistamine with appetite effect — tablet and syrup formulations for allergy and appetite support.

vasopressin V2-analogue peptide — tablet, spray and injection formulations for central diabetes insipidus and nocturia.

antimuscarinic — tablet formulations, including extended-release, for overactive bladder.

antimuscarinic with calcium-blockade — tablet formulations for overactive bladder.

quaternary antimuscarinic — tablet formulations for overactive bladder.

second-generation nonsedating antihistamine — tablet and suspension formulations for allergic rhinitis and urticaria.

broad-spectrum benzimidazole anthelmintic — tablet and suspension formulations for intestinal worms and tissue parasites.

artemisinin derivative — injection and combination tablet formulations for falciparum malaria.

artemisinin derivative, first-line for severe malaria — injection and tablet formulations for uncomplicated and severe malaria.

4-aminoquinoline antimalarial — tablet and injection formulations for sensitive malaria strains.

4-aminoquinoline for malaria, lupus and rheumatoid arthritis — tablet formulations across rheumatology and dermatology.

avermectin antiparasitic — tablet formulations for strongyloidiasis, scabies and onchocerciasis.

benzimidazole anthelmintic — chewable tablet and suspension formulations for intestinal worms.

Proton pump inhibitor API for gastro-resistant tablets and injectables.

first-generation nucleoside herpes antiviral — tablet, cream and injection formulations for HSV and VZV.

NS5A inhibitor for hepatitis C — tablet formulations within HCV direct-acting regimens.

second-generation protease inhibitor — tablet formulations for HIV-1 therapy.

guanosine analogue for hepatitis B — tablet formulations for chronic hepatitis B.

nucleoside reverse transcriptase inhibitor — tablet and solution formulations for HIV and hepatitis B.

NS5A inhibitor for hepatitis C — tablet formulations in sofosbuvir combination therapy.

CCR5 antagonist antiretroviral — tablet formulations within individualised HIV regimens.

nucleotide analogue antiviral — injection formulations for hospitalised viral infections.

NS5B polymerase inhibitor for hepatitis C — tablet formulations as the backbone of HCV direct-acting regimens.

targeted prodrug of tenofovir — tablet formulations for HIV and hepatitis B with a improved renal profile.

High-volume NSAID API, DC and powder grades, multi-tonne supply.

nucleotide reverse transcriptase inhibitor — tablet formulations for HIV and hepatitis B, alone and in combinations.

prodrug of acyclovir with higher oral exposure — tablet formulations for herpes zoster, HSV and CMV prophylaxis.

pan-genotypic NS5A inhibitor — tablet formulations in sofosbuvir combination therapy for all HCV genotypes.

anti-TNF monoclonal antibody — injection formulations for rheumatoid arthritis, IBD and psoriasis.

PDE4 inhibitor — tablet formulations for psoriasis and psoriatic arthritis.

microtubule inhibitor for gout — tablet formulations for acute gout and familial Mediterranean fever.

TNF receptor fusion protein — injection formulations for rheumatoid arthritis and psoriasis.

xanthine oxidase inhibitor — tablet formulations for chronic hyperuricaemia in gout.

chimeric anti-TNF monoclonal antibody — injection formulations for rheumatoid arthritis, IBD and psoriasis.

recombinant PTH analogue — pen formulations for severe osteoporosis.

NSAID API for tablets, gels and injectables.

JAK inhibitor — tablet formulations for rheumatoid arthritis and ulcerative colitis.

endothelin receptor antagonist — tablet formulations for pulmonary arterial hypertension.

class III antiarrhythmic — tablet and injection formulations for ventricular and atrial arrhythmias.

cardioselective beta blocker — tablet formulations for hypertension and angina.

first ACE inhibitor — tablet formulations for hypertension and heart failure.

carnitine supplement for fat metabolism — tablet, solution and injection formulations for carnitine deficiency and dialysis care.

dual endothelin receptor antagonist — tablet formulations for pulmonary arterial hypertension.

cardioselective beta blocker — tablet formulations for hypertension, angina and heart failure.

dihydropyridine calcium channel blocker — tablet and capsule formulations for hypertension and angina.

high-potency statin — tablet formulations for LDL-cholesterol reduction.

Second-generation antihistamine API, IP/BP/USP grades.

ARNI — neprilysin inhibitor plus ARB — tablet formulations for chronic heart failure with reduced ejection fraction.

free-radical scavenger — injection formulations for amyotrophic lateral sclerosis and stroke care.

calcium channel blocker for migraine prophylaxis — tablet formulations for migraine and vertigo.

alpha-2-delta ligand for neuropathic pain — capsule and tablet formulations for neuropathic pain and as adjunct in epilepsy.

pooled human normal immunoglobulin — injection formulations for immunodeficiency and neurological indications.

alpha-2-delta ligand — capsule formulations for neuropathic pain, fibromyalgia and as antiepileptic adjunct.

5-HT1B/1D agonist — tablet and wafer formulations for acute migraine.

anticholinergic antiparkinsonian — tablet and syrup formulations for parkinsonism and drug-induced extrapyramidal symptoms.

second-generation retinoid — capsule formulations for severe psoriasis.

keratolytic and antibacterial acne agent — gel and wash formulations for acne, alone and in combinations.